{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:05Z","timestamp":1787013905399,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1111431"],"award-info":[{"award-number":["OPP1111431"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["615\u201073099\u2010MT2016KFW"],"award-info":[{"award-number":["615\u201073099\u2010MT2016KFW"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID\u2010OAA\u2010G14\u201000010"],"award-info":[{"award-number":["AID\u2010OAA\u2010G14\u201000010"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Emodepside is an anthelmintic, originally developed for veterinary use. We investigated in healthy subjects the safety, and pharmacokinetics of a liquid service formulation (LSF) and immediate release (IR) tablet of emodepside in 2 randomised, parallel\u2010group, placebo\u2010controlled, Phase I studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy\u2010nine subjects in 10 cohorts in the single ascending dose study and 24 subjects in 3 ascending\u2010dose cohorts in the multiple ascending dose study were enrolled. Emodepside as LSF was administered orally as single 1\u201340\u2010mg doses and for 10\u00a0days as 5 or 10\u00a0mg once daily and 10\u2010mg twice daily doses, respectively. Pharmacokinetics and safety were assessed up to 21 and 30\u2009days, respectively. In addition, IR tablets containing 5 or 20\u2009mg emodepside were tested in the single ascending dose study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Emodepside as LSF was rapidly absorbed under fasting conditions, with dose\u2010proportional increase in plasma concentrations at doses from 1 to 40\u2009mg. Terminal half\u2010life was &gt; 500\u2009hours. In the fed state, emodepside was absorbed more slowly but overall plasma exposure was not significantly affected. Compared to the LSF, the rate and extent of absorption was significantly lower with the tablets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, emodepside had acceptable safety and tolerability profiles, no major safety concerns, after single oral administration of 20\u2009mg as LSF and after multiple oral administration over 10\u00a0days at 5 and 10\u00a0mg OD and at 10\u00a0mg twice daily. For further clinical trials, the development of a tablet formulation overcoming the limitations observed in the present study with the IR tablet formulation is considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.14816","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T04:53:59Z","timestamp":1616561639000},"page":"3949-3960","source":"Crossref","is-referenced-by-count":27,"title":["Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-0403","authenticated-orcid":false,"given":"Jean\u2010Yves","family":"Gillon","sequence":"first","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-0614","authenticated-orcid":false,"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[{"name":"Hammersmith Medicines Research Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-3910","authenticated-orcid":false,"given":"Frans","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Hammersmith Medicines Research Ltd  London UK"},{"name":"Invicro, Burlington Danes Building Imperial College London, Hammersmith Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Delhomme","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dequatre Cheeseman","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pe\u00f1a Rossi","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-6934","authenticated-orcid":false,"given":"Nathalie","family":"Strub Wourgaft","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-5812","authenticated-orcid":false,"given":"Sabine","family":"Specht","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Pedrique","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Monnot","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi)  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Skrabs","sequence":"additional","affiliation":[{"name":"Bayer AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u2010Luisa","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Bayer AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heino","family":"Stass","sequence":"additional","affiliation":[{"name":"Bayer AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organisation.Onchocerciasis (river blindness) \u2010 DiseaseInformationhttps:\/\/www.who.int\/blindness\/partnerships\/onchocerciasis_disease_information\/en\/consultedon 14 April2020"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2016.04.002"},{"key":"e_1_2_10_4_1","first-page":"81","article-title":"Onchocerciasis Elimination: Progress and Challenges","volume":"11","author":"Lakwo T","year":"2020","journal-title":"Res Rep Trop Med"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000998"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32844-1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1048"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257456"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182004006523"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003401"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0664fje"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2012.06.005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004360100479"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00219-X"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(01)00263-6"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(01)00144-9"},{"key":"e_1_2_10_17_1","unstructured":"Drugs for Neglected Diseasesinitiative.Investigator Brochure Emopdepside \u2010 BAY 44\u20134400. Version 3 dated 8 September2017"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"e_1_2_10_19_1","volume-title":"Beck Depression Inventory\u2010Second Edition Manual","author":"Beck AT","year":"1996"},{"key":"e_1_2_10_20_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Guideline on strategies to identify and mitigate risks for first\u2010in\u2010human and early clinical trials with investigational medicinal products. EMEA\/CHMP\/SWP\/28367\/07 Rev. 1. July2017"},{"key":"e_1_2_10_21_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).ICH Topic E 9. Statistical Principles for Clinical Trials. EMEA\/CPMP\/ICH\/363\/96.September 1998"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:34:24Z","timestamp":1693341264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/bcp.14816"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14816","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}